HUP0302194A2 - A kemokin-mutánsok a sclerosis multiplex kezelésében - Google Patents

A kemokin-mutánsok a sclerosis multiplex kezelésében

Info

Publication number
HUP0302194A2
HUP0302194A2 HU0302194A HUP0302194A HUP0302194A2 HU P0302194 A2 HUP0302194 A2 HU P0302194A2 HU 0302194 A HU0302194 A HU 0302194A HU P0302194 A HUP0302194 A HU P0302194A HU P0302194 A2 HUP0302194 A2 HU P0302194A2
Authority
HU
Hungary
Prior art keywords
treatment
multiple sclerosis
chemokine mutants
chemomutants
rantes
Prior art date
Application number
HU0302194A
Other languages
English (en)
Inventor
Marie Kosco-Vilbois
Amanda Proudfoot
Timothy N.C. Wells
Original Assignee
Applied Research Systems Ars Holding N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems Ars Holding N.V. filed Critical Applied Research Systems Ars Holding N.V.
Publication of HUP0302194A2 publication Critical patent/HUP0302194A2/hu
Publication of HUP0302194A3 publication Critical patent/HUP0302194A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A találmány tárgyát olyan kemokimutánsok képezik, amelyekszerkezetében a 40-es hurok kationos helyén legalább két mutációttartalmaznak, és amelyek a vadtípusú molekulával összehasonlítvacsökkent GAG-kötő aktivitást mutatnak. Különösképpen, azt figyelhetőmeg, hogy az ilyen mutált kemokinek hatékonyak a sclerosis multiplexés/vagy más, a mielinpusztulással járó betegségek kezelésében. Aháromszoros mutációt hordozó RANTES az a vegyület, amely a legjobberedményeket mutatta. Ó
HU0302194A 2000-10-04 2001-10-03 Chemokine mutants in the treatment of multiple sclerosis HUP0302194A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00121665 2000-10-04
PCT/EP2001/011428 WO2002028419A2 (en) 2000-10-04 2001-10-03 Chemokine mutants in the treatment of multiple sclerosis

Publications (2)

Publication Number Publication Date
HUP0302194A2 true HUP0302194A2 (hu) 2003-10-28
HUP0302194A3 HUP0302194A3 (en) 2005-12-28

Family

ID=8170011

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0302194A HUP0302194A3 (en) 2000-10-04 2001-10-03 Chemokine mutants in the treatment of multiple sclerosis

Country Status (31)

Country Link
US (1) US7402303B2 (hu)
EP (1) EP1326628B1 (hu)
JP (1) JP3908165B2 (hu)
KR (1) KR100837898B1 (hu)
CN (1) CN1285381C (hu)
AR (1) AR030854A1 (hu)
AT (1) ATE265222T1 (hu)
AU (2) AU2002215919B2 (hu)
BG (1) BG66137B1 (hu)
BR (1) BR0114407A (hu)
CA (1) CA2423616C (hu)
CZ (1) CZ303409B6 (hu)
DE (1) DE60103078T2 (hu)
DK (1) DK1326628T3 (hu)
EA (1) EA006137B1 (hu)
EE (1) EE05174B1 (hu)
ES (1) ES2217199T3 (hu)
HK (1) HK1062811A1 (hu)
HR (1) HRP20030215B1 (hu)
HU (1) HUP0302194A3 (hu)
IL (2) IL155178A0 (hu)
MX (1) MXPA03003008A (hu)
NO (1) NO330278B1 (hu)
PL (1) PL204231B1 (hu)
PT (1) PT1326628E (hu)
RS (1) RS50738B (hu)
SI (1) SI1326628T1 (hu)
SK (1) SK287523B6 (hu)
UA (1) UA77950C2 (hu)
WO (1) WO2002028419A2 (hu)
ZA (1) ZA200302315B (hu)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005525089A (ja) 2001-12-17 2005-08-25 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ ケモカイン・アンタゴニストとして作用するケモカイン突然変異体
SI1494703T1 (sl) * 2002-04-04 2006-06-30 Applied Research Systems Mutanti hemokinov z izboljsano oralno biorazpolozljivostjo
AU2003302755B2 (en) * 2002-12-23 2009-01-08 Laboratoires Serono Sa Use of CC-chemokine mutants against liver diseases
EP1673388B1 (en) * 2003-10-22 2008-11-26 Laboratoires Serono SA Cxcl8 antagonists
AT412785B (de) * 2003-12-04 2005-07-25 Kungl Andreas J Dr Gag-bindungsproteine
DK1439191T3 (da) * 2004-01-19 2006-08-14 Ares Trading Sa Proces til oprensning af bakterielt udtrykte proteiner
GB0412400D0 (en) * 2004-06-03 2004-07-07 Univ Newcastle Treatment of inflammatory conditions
EP1760110B1 (en) * 2005-09-03 2011-11-02 Samsung SDI Co., Ltd. Polybenzoxazine-based compound, electrolyte membrane including the same, and fuel cell employing the electrolyte membrane
GB0614755D0 (en) 2006-07-25 2006-09-06 Univ Geneve Cytokine derivatives
EP2185719B1 (en) 2007-08-02 2013-11-13 NovImmune SA Anti-rantes antibodies and methods of use thereof
CN102781952B (zh) * 2010-02-08 2015-09-02 宾夕法尼亚大学托管会 编码rantes的核酸分子、包含其的组合物以及其使用方法
US20210205412A1 (en) 2018-05-28 2021-07-08 Université De Genève Methods of inhibiting cerebral inflammation
WO2022093857A1 (en) * 2020-10-26 2022-05-05 City Of Hope Oncolytic virus compositions and methods for the treatment of cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739103A (en) 1993-11-12 1998-04-14 Dana-Farber Cancer Institute Chemokine N-terminal deletion mutations
WO1998006751A1 (en) 1996-08-16 1998-02-19 Research Corporation Technologies, Inc. Mcp-3, rantes and mip-1alpha receptor antagonists
EP0906954A1 (en) * 1997-09-29 1999-04-07 Applied Research Systems ARS Holding N.V. Amino-terminal truncated c-c chemokines as chemokine antagonist
ES2247738T3 (es) 1997-12-23 2006-03-01 Fondazione Centro San Raffaele Del Monte Tabor Mutantes de rantes y sus aplicaciones terapeuticas.
CA2361256A1 (en) 1999-01-29 2000-08-03 James B. Rottman Method of treating demyelinating inflammatory disease using ccr1 antagonists

Also Published As

Publication number Publication date
ES2217199T3 (es) 2004-11-01
EE05174B1 (et) 2009-06-15
US20040101509A1 (en) 2004-05-27
CN1285381C (zh) 2006-11-22
PL362350A1 (en) 2004-10-18
CZ2003947A3 (cs) 2003-11-12
ZA200302315B (en) 2004-03-25
JP3908165B2 (ja) 2007-04-25
PL204231B1 (pl) 2009-12-31
MXPA03003008A (es) 2003-07-14
WO2002028419A2 (en) 2002-04-11
EA006137B1 (ru) 2005-10-27
CA2423616C (en) 2010-03-16
UA77950C2 (en) 2007-02-15
CZ303409B6 (cs) 2012-09-05
EP1326628B1 (en) 2004-04-28
IL155178A (en) 2009-07-20
CN1477969A (zh) 2004-02-25
BR0114407A (pt) 2003-07-29
HRP20030215A2 (en) 2005-02-28
CA2423616A1 (en) 2002-04-11
DE60103078D1 (de) 2004-06-03
SI1326628T1 (en) 2004-10-31
SK4062003A3 (en) 2003-08-05
RS50738B (sr) 2010-08-31
YU25703A (sh) 2006-05-25
EP1326628A2 (en) 2003-07-16
US7402303B2 (en) 2008-07-22
HRP20030215B1 (en) 2011-09-30
HUP0302194A3 (en) 2005-12-28
DE60103078T2 (de) 2005-04-07
EE200300139A (et) 2003-06-16
AU1591902A (en) 2002-04-15
BG107685A (bg) 2003-11-28
AU2002215919B2 (en) 2005-11-24
NO20031525L (no) 2003-04-03
NO20031525D0 (no) 2003-04-03
EA200300439A1 (ru) 2003-08-28
KR100837898B1 (ko) 2008-06-13
KR20030034238A (ko) 2003-05-01
SK287523B6 (sk) 2011-01-04
IL155178A0 (en) 2003-11-23
ATE265222T1 (de) 2004-05-15
BG66137B1 (bg) 2011-07-29
AR030854A1 (es) 2003-09-03
NO330278B1 (no) 2011-03-21
PT1326628E (pt) 2004-09-30
HK1062811A1 (en) 2004-11-26
DK1326628T3 (da) 2004-08-09
WO2002028419A3 (en) 2002-06-13
JP2004510426A (ja) 2004-04-08

Similar Documents

Publication Publication Date Title
HUP0302194A2 (hu) A kemokin-mutánsok a sclerosis multiplex kezelésében
IL214607A0 (en) 2,4-pyrimidinedinediamine compounds and their use in the manufacture of medicaments for the treatment of autoimmune disases
WO2005012294A8 (en) 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
CA2171882A1 (en) Inhibitors of .beta.-amyloid protein production
ATE199906T1 (de) Phosphonat-nukleotid ester-derivate
NO20035025D0 (no) Anvendelse av osteopontin for behandling og/eller for å hindre nevrologiskesykdommer
ATE200618T1 (de) Ssi tyrphostine und pharmazeutische zusammensetzungen
USD457718S1 (en) Toothpaste and toothbrush travel holder
ATE421974T1 (de) Chemokine mutanten, die als chemokine antagonisten wirken
CA2385440A1 (en) 5-hydroxysapogenin derivatives with anti-dementia activity
ES2189206T3 (es) Beta-alcoxiacrilatos contra la malaria.
EP1199372A3 (en) Polymorphisms in the human P2X7 gene
FR2699523B1 (fr) Phyllosilicates de synthèse et procédé pour leur préparation.
IT8819447A0 (it) Composizione di composti che migliorano l'attivita' analgesica, antipiretica e antinfiammatoria.
EP1741722A3 (en) Polymorphisms in the human P2X7 gene
IT9082546A1 (it) Abbattimento del fosforo, dell'azoto e dei metalli pesanti presenti nelle acque con estratti di astrolite e possibile loro utilizzo nei procedimenti di denitrificazione delle acque.
Kaidash et al. INVESTIGATION OF THE STRUCTURE AND PROPERTIES OF BORIDE COATINGS ON STEEL
Zamotaev et al. Side effects caused by antibacterial agents.
ITMI961070A0 (it) Prevenzione e trattamento delle infezioni virali topiche con perfluoropolietere o loro composizioni.
IT1308107B1 (it) Procedimento di digitalizzazione diretta ed indiretta di manoscrittiantichi attraverso processi di riproduzione, recupero dell'aspetto
TH42347EX (th) เก้าอี้
RU96106581A (ru) Препарат для лечения гнойно-воспалительных заболеваний
ZA986219B (en) Use of compositions containing the combination of acetaminophen, aspirin and caffeine to alleviate the pain and symptoms of migraine.

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished